TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Enorama Pharma AB
Closing information (x1000 EUR)
| Closing information | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
1,373
|
122
|
615 |
| Financial expenses |
260
|
323
|
188 |
| Earnings before taxes |
-3,814
|
-4,021
|
-3,777 |
| EBITDA |
-2,360
|
-3,477
|
-3,409 |
| Total assets |
1,384
|
3,099
|
4,378 |
| Current assets |
1,320
|
1,168
|
1,056 |
| Current liabilities |
704
|
921
|
1,117 |
| Equity capital |
679
|
1,761
|
2,833 |
| - share capital |
823
|
576
|
131 |
| Employees (average) |
5
|
5
|
9 |
Financial ratios
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
49.1%
|
56.8%
|
64.7% |
| Turnover per employee |
275
|
24
|
68 |
| Profit as a percentage of turnover |
-277.8%
|
-3295.9%
|
-614.1% |
| Return on assets (ROA) |
-256.8%
|
-119.3%
|
-82.0% |
| Current ratio |
187.5%
|
126.8%
|
94.5% |
| Return on equity (ROE) |
-561.7%
|
-228.3%
|
-133.3% |
| Change turnover |
1,255
|
-495
|
-376 |
| Change turnover % |
1061%
|
-80%
|
-38% |
| Chg. No. of employees |
0
|
-4
|
-1 |
| Chg. No. of employees % |
0%
|
-44%
|
-10% |
Total value of public sale
| Fiscal year | 2024/12 (consolidated) | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.